Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on discovering and developing medicines that target the chromatin regulatory system and abnormal gene expression. It monetizes its proprietary Gene Traffic Control platform through collaboration agreements and internal pipeline development, particularly in oncology.

Relationship details are part of the Pro plan.